|
Wednesday, June 11
|
| 8:00 - 5:00pm |
Registration & Morning Coffee |
| 8:00 - 9:00am |
Visit Exhibits/Poster Viewing in Exhibit Hall |
| 8:50 - 9:00am |
Opening Remarks |
| 9:00 - 9:05am |
Keynote Introduction |
| |
Session 3 - Hit Finding & Hit Validation |
Session 4 - Mode of Action & ADME |
| 9:10 - 10:00am |
The Evolution of Real-Time Label-Free Biosensor Applications - Keynote Presentation Details^
David Myszka, University of Utah, USA |
| 10:00 - 10:30am |
Networking/Refreshment Break in Exhibit Hall |
| 10:30-11:00am |
SPR Based Direct Binding Assays in Drug Discovery Details^
Walter Huber, F. Hoffmann-La Roche, Switzerland |
Towards a More Efficient & Faster Lead Optimization Details^
Ernesto Freire, Johns-Hopkins University, USA |
| 11:00 - 11:30am |
Productive & Promiscuous Hits - Biophysical/Label-Free Assays in Hit Discovery & Verification Details^
Johannes Ottl, Novartis, Switzerland |
Integration of Biophysical Methods into the Drug Discovery Process Details^
Matthias Frech, Merck KGaA, Germany |
| 11:30 - 12:00 pm |
Harnessing Optical Label-Free on Microtiter Plates for Lead Finding: From Binding to Phenotypes Details^
Julio Martin, GlaxoSmithKline, Spain |
What Drug Binding Properties Should be Captured in Drug Discovery Lead Identification & Optimization Assays? Details^
David Swinney, Roche, USA |
| 12:00 - 12:30pm |
Applying Label-Free Technologies to Validate Screening Hits Details^
David Mark, Sr., Roche, USA |
Use of Label-Free Detection Technologies in the Hit-to-Lead Process Details^
Frank Stuhmeier, Pfizer, UK |
| 12:30 - 2:00pm |
Lunch/Visit Exhibits/Poster Viewing in Exhibit Hall |
| 2:00 - 2:30pm |
Lead Identification & Confirmation Using a Label-Free Affinity-Based Screening Platform Details^
David J. Burns, Abbott, USA |
Label-Free Cellular-Based Assays: Relevance to GPCR Drug Discovery Details^
Jeff Jerman, GlaxoSmithKline, UK |
| 2:30 - 3:00pm |
High-Throughput, Solution-Based Protein Stability Measurements via ThermoFluor(R) Technology Details^
Matthew J. Todd, Johnson & Johnson R&D, USA |
Nonradioactive Rb+ Efflux Assay Technology for Screening of Ion Channels Details^
Georg Terstappen, Sienna Biotech, Italy |
| 3:00 - 3:30pm |
Networking/Refreshment Break |
| 3:30 - 4:15pm |
Tutorials Program II
MDS Analytical Technologies
The CellKey™ Product Family: A platform for the full range of early drug discovery applications
Details^
Speaker: Ryan McGuinness. Senior Application Scientist, MDS Analytical Technologies
Room: Seminar 1
ForteBio
Hit Validation Using Biolayer Interferometry
Details^
Speaker: Frank Podlaski, Sr. Principal Scientist Hoffman LaRoche, Nutley, NJ
Room: Seminar 2
FUJIFILM Medical Systems
A Fully Automated Workstation for High Throughput, High Sensitivity Surface Plasmon Resonance
Details^
Speakers: Nobuhiko Ogura, FUJIFILM Corporation and Al Kolb, KeyTech Solutions
Room: Seminar 3/4
|
| 4:15 - 4:45pm |
The Pyramid Approach to Fragment-Based Biophysical Screening Details^
Glyn Williams, Astex Therapeutics, Ltd., UK |
A Bona Fide High Throughput Screening Campaign to Identify Agonist Compounds Using the 384 Well Cell-based Label-Free Epic® System
from Corning® Details^
Ralph J. Garippa, Roche, USA |
| 4:45 - 5:15pm |
Development of High-Throughput Mass Spectrometric (HTMS) Methods for Underivatized Small Molecules in Biological Samples Spanning in
vitro,
Cell Culture, and ex-vivo Assays Details^
Can Ozbal, BioTrove, Inc., USA |
The Generation and Characterization of Conformation-Dependent G-protein Antibodies Details^
Melanie Jay, GlaxoSmithKline, UK |
